Newsom Appoints Dr. Stephen Juelsgaard to CIRM Governing Board


Lieutenant Governor Newsom today announced the appointment of Stephen Juelsgaard, former executive vice president, secretary and chief compliance officer of Genentech, Inc., to the Independent Citizens Oversight Committee (ICOC), the governing board of the California Institute of Regenerative Medicine. Dr. Juelsgaard fills the California life science commercial entity appointment. He currently teaches at the Stanford Law School and is a member of the Board of Directors of Ivivi Health Sciences LLC, a private medical device company.

“Stephen’s 24 years of experience in the field of biotechnology make him uniquely qualified to fill this vacancy,” said Lt. Governor Gavin Newsom. “His knowledge and experience will be invaluable in helping to advance California’s world-class reputation in regenerative medicine.”

“Dr. Stephen Juelsgaard brings an extraordinary background to the Board, particularly focused on the intellectual property and legal issues that confront any therapy in development,” said CIRM Governing Board Chair, Robert Klein. “As the General Counsel for Genentech, Dr. Juelsgaard was a critical contributor to their development of a broad base of medical therapies that have helped patients throughout the world.”

Juelsgaard joined Genentech in 1985 as corporate counsel and became senior corporate counsel in 1989. In 1992, he became vice president of Corporate Law and served as general council from 1994 through 2007. In 1997, Juelsgaard was named secretary to the Board of Directors and a senior vice president in 1998. In 2002, he was appointed executive vice president, in 2005 was named chief compliance officer, and in 2007 he became responsible for oversight of the Government Affairs group. Juelsgaard was the company’s representative on the board of directors of the California Healthcare Institute from 2005 until 2009.

“I'm honored to be asked to join the ICOC and believe that the role of CIRM in providing critical support for the development of stem cell therapy is instrumental in helping make its promise a reality,” said Dr. Juelsgaard. “I look forward to using my experience in biotechnology to help CIRM further its mission and goals.”

Prior to joining Genentech, Juelsgaard was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati in Palo Alto, California.

Dr. Juelsgaard received his Doctor of Veterinary Medicine degrees from Iowa State University in 1972 and a Masters Degree in Veterinary Clinical Sciences in 1975 from Iowa State University. In 1982, he received his Juris Doctorate degree from Stanford Law School.

About CIRM
CIRM was established in November 2004 with the passage of Proposition 71, the California Stem Cell Research and Cures Act. The statewide ballot measure, which provided $3 billion in funding for stem cell research at California universities and research institutions, was overwhelmingly approved by voters, and called for the establishment of an entity to make grants and provide loans for stem cell research, research facilities, and other vital research opportunities. A list of grants and loans awarded to date may be seen here: